Ravi Kasiappan, Ph.D.
Professional Vision
Bringing innovative solutions to preclinical drug discovery and translational biomarker sciences, advancing therapeutics for cancer and immune-related diseases. Committed to bridging research and clinical applications to improve patient outcomes.
Vision
To contribute towards making India self-sufficient and an economic leader by transforming it into a globally sought-after hub for Animation, Graphics, and Technology-driven industries, including Cloud and AI.
Key Accomplishments
- Preclinical Drug Discovery: Designed and implemented in vivo oncology studies for AbbVie, supporting IND submissions with novel tumor models and biomarker analyses.
- COVID-19 Research: Developed in vitro pseudovirus and in vivo SARS-CoV-2 models for screening small molecules and neutralizing antibodies.
- High-Impact Research: Identified miR-3184 and miR-181c as biomarkers for obesity-associated breast cancer; demonstrated novel drug mechanisms targeting SP transcription factors and ROS-mediated cMYC inhibition.
- Innovation in Assays: Established high-throughput screening (HTS) systems for small molecules and ligand-receptor assays (e.g., TR-FRET, luciferase reporter assays).
